Literature DB >> 862206

Glucagon and diabetes. II. Complete suppression of glucagon by insulin in human diabetes.

G L Warne, F P Alford, D J Chisholm, J Court.   

Abstract

In order to determine whether glucagon levels of diabetic subjects are suppressible, alpha cell responsiveness to acute insulin administration (0.1 units/kg intravenously) was determined in fourteen juvenile onset, healthy diabetic and eight control subjects. In the diabetics, insulin produced a significant but slow fall in blood glucose over 60 min (P less than 0.01). On the other hand, glucagon levels fell dramatically in all diabetics to undetectable levels (P less than 0.001). Only one diabetic became hypoglycaemic and he alone showed a rebound rise of glucagon at 60 min. The rate of fall of blood glucose in the diabetic subjects was not influenced by the basal glucagon level (r=0.13) or the rate of fall of plasma glucagon (r=0.04). The glucose and glucagon responses of control subjects to insulin administration were in sharp contrast to the diabetics: blood glucose levels fell rapidly to hypoglycaemic levels and were associated with a major rise in glucagon levels (mean rise 116 pmol/1, P less than 0.001). We conclude that alpha cell hyperfunction in human diabetes can be completely suppressed by insulin administration and is therefore not autonomous, and that the slow rate of fall of blood glucose following insulin administration in diabetics is not secondary to glucagon excess.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 862206     DOI: 10.1111/j.1365-2265.1977.tb02012.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  2 in total

1.  Regulation of glucagon release: effects of insulin on the pancreatic A2-cell of the guinea pig.

Authors:  C G Ostenson
Journal:  Diabetologia       Date:  1979-11       Impact factor: 10.122

2.  Relationship of glucagon suppression by insulin and somatostatin to the ambient glucose concentration.

Authors:  A Starke; T Imamura; R H Unger
Journal:  J Clin Invest       Date:  1987-01       Impact factor: 14.808

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.